GlassScriptPhysician profile
Michelle Miller
NPI 1386309557
$2,114.33
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,299 · 2023: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $422.90 | 2022-2023 | Vumerity, Tysabri, Avonex |
| Abbvie INC. | $161.92 | 2022-2023 | |
| Lundbeck LLC | $136.57 | 2022-2023 | Vyepti |
| Lilly USA, LLC | $119.31 | 2022-2023 | Reyvow, Emgality |
| Ucb, INC. | $115.88 | 2022-2023 | Briviact |
| Sk Life Science, INC. | $89.85 | 2022-2023 | |
| Amgen INC. | $73.78 | 2022 | |
| Celgene Corporation | $73.76 | 2022-2023 | Zeposia |
| Biohaven Pharmaceutical Holding Company LTD. | $70.33 | 2022 | |
| Amneal Pharmaceuticals LLC | $67.95 | 2022-2023 | Rytary |
| Csl Behring | $64.66 | 2022-2023 | Hizentra |
| Kyowa Kirin, INC. | $55.19 | 2022-2023 | Nourianz |
| Janssen Pharmaceuticals, INC | $54.03 | 2022-2023 | Ponvory |
| Amylyx Pharmaceuticals, INC. | $52.02 | 2023 | Relyvrio |
| Novartis Pharmaceuticals Corporation | $50.22 | 2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45.43 | 2022-2023 | Austedo |
| Scilex Pharmaceuticals INC. | $43.08 | 2022 | |
| Pfizer INC. | $41.92 | 2023 | |
| Impel Pharmaceuticals INC. | $40.03 | 2023 | Trudhesa |
| Insightec,INC | $37.69 | 2022-2023 | Exablate |
| Jazz Pharmaceuticals INC. | $30.18 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $30.01 | 2022-2023 | Purified Cortrophin Gel |
| Neurelis, INC. | $26.75 | 2022 | |
| Supernus Pharmaceuticals, INC. | $26.55 | 2022 | |
| Aprecia Pharmaceuticals, LLC | $25.97 | 2022 | |
| Tg Therapeutics, INC. | $17.42 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.52 | 2022 | |
| Merz Pharmaceuticals, LLC | $14.98 | 2023 | Xeomin |
| Eisai INC. | $14.90 | 2023 | |
| Octapharma USA, INC. | $14.81 | 2022 | |
| Acorda Therapeutics, INC | $14.31 | 2022 | |
| Argenx US, INC. | $14.19 | 2023 | Vyvgart |
| Otsuka America Pharmaceutical, INC. | $14.15 | 2023 | Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $13.44 | 2023 | Gammagard |
| Axsome Therapeutics, INC. | $12.97 | 2023 | Sunosi |
| Mallinckrodt Hospital Products INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.